Programme
Accelerate Alumni (Cohort 4)
Founded in
2014
Total funds raised
£66.4 million
Employees
51-100
Industry
Healthcare, pharma, biotech
At the centre of Healx’s approach is its next-generation AI platform built to find novel connections between drugs and diseases. Healx combine these predictions with inhouse expertise to accelerate new treatments through their pipeline to clinical trials and on to patients.
Rare diseases are often not well studied and there is a limited understanding of many of the aspects necessary to support a drug discovery programme. Healx’s AI platform overcomes these challenges by analysing millions of drug and disease data points to find novel connections that could be turned into new treatment opportunities. By applying frontier technologies across the discovery and development pipeline, Healx can run multiple stages in parallel and at scale.
Get in touch
News about Healx
Misc news
Award-winning startups
Companies associated with Cambridge Judge Business School were honoured in the Cambridge Independent Science and Technology Awards.
Healx, a biotech firm that was supported by the Entrepreneurship Centre at Cambridge Judge Business School, says it is using its artificial intelligence (AI) platform to develop drug combinations from approved drugs to seek treatments for COVID-19.
Programme news
Movers and shakers
Five women associated with Cambridge Judge Business School are named in BioBeat report on 50 top women leaders and innovators in biotech.
Press coverage on Healx
Healx | 1 August 2024
Healx announces $47 million Series C financing and FDA clearance of phase 2 IND for neurofibromatosis type 1 trial
Series C round co-led by R42 Group and Atomico, and joined by new/current investors; Financing to advance expanding rare disease pipeline U.S. FDA has cleared its investigational new drug (IND) application to advance HLX-1502 in Phase 2 clinical trial in NF1; Healx to initiate Phase 2 clinical trial by end of year Healx, co-founded by co-inventor of Viagra, harnesses AI to specifically discover new treatments for rare diseases